August 1, 2018
Whom It May Concern
Company:KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President(Security Code: 4569, TSE 1st Sec.)Contact:Shuji Miyaki
Director, Corporate Communication
President OfficeTelephone:(0)3-3525-4707

KYORIN Pharmaceutical and FAES Farma Sign Agreement
on Development and Distribution of Imidafenacin in Latin America
TOKYO, Japan (August 1, 2018) — KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan,President: Minoru Hogawa, “Kyorin Pharmaceutical”), a subsidiary of KYORIN Holdings, Inc., has
executed a collaboration agreement with FAES FARMA, S.A. (Head office: Leioa, Spain, President:
Mariano Ucar Angulo, “FAES”) for the exclusive development and distribution rights to Imidafenacin,a treatment for overactive bladder (OAB) that was discovered and developed by Kyorin
Pharmaceutical, in Latin America (13 central and south countries including Brazil and Mexico).
Imidafenacin is a novel anticholinergic agent that acts as a selective antagonist on M3 and M1
muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary
incontinence associated with OAB. In Japan, Kyorin Pharmaceutical launched Imidafenacin underthe brand name Uritos® 0.1mg tablets in June 2007. An additional dosage form of Orally
Disintegrating (OD) tablet was launched in April 2011.
Under the philosophy to contribute to the health of people around the world, Kyorin Pharmaceuticalcontinues to be actively engaged in the penetration of this agent in Japan and contributes to the QOLof patients suffering from symptoms of OAB. Further to such commitment, Kyorin Pharmaceuticalaims to spread Imidafenacin in the market of Latin America with the partnership with FAES, andpromotes its business globally.
It is expected that the impact of this transaction on consolidated financial forecasts for the fiscal year
ending March 31, 2019 would be negligible.
###About FAES FARMA S.A.
Established in:
President:
Revenue:
Employees:
Overview:

1933
Mariano Ucar Angulo
EUR 274.6 million (2017)
1,174
Founded in 1933, FAES Farma is a Spanish pharmaceutical company with awide-ranging international projection, which develops, produces andcommercializes pharmaceutical products and raw materials, exporting themto many countries.
The hallmarks of the company are an unrelenting commitment to excellence,constant striving for maximum pharmacological quality in all products withhard work that aims to offer highly effective solutions for patients.
FAES Farma is present in many countries, employing more than 1.100
people in its headquarters in Madrid, R&D center in Bilbao, the Vitoria
laboratory in Lisbon and Diafarm laboratory, and its subsidiary companies
and commercial offices abroad. It also owns the animal nutrition andhealthcare companies Ingaso Farm, Tecnovit and Itf.
For more information, please visit faesfarma.com.

About OAB
Overactive Bladder (OAB) is a urological conditions characterized by difficulty in pooling urine in
the bladder. Its predominant symptom is an urge to urinate, which is often accompanies byfrequent urination and nocturia, and in some cases by urge urinary incontinence. One of the major
problems of OAB is the fact that patients refrain from leaving the house due to anxiety about goingto the bathroom, cannot get enough sleep at night, or face limitations in their daily activities, which
could lead to significantly-reduced quality of life. Anticholinergic agents that show antagonistic
effects, mainly on muscarinic receptors, are thought to be effective in treating OAB.